AR077241A1 - Metodo de tratamiento del cancer conantagonista dll4 y agente quimioterapeutico - Google Patents
Metodo de tratamiento del cancer conantagonista dll4 y agente quimioterapeuticoInfo
- Publication number
- AR077241A1 AR077241A1 ARP100102269A ARP100102269A AR077241A1 AR 077241 A1 AR077241 A1 AR 077241A1 AR P100102269 A ARP100102269 A AR P100102269A AR P100102269 A ARP100102269 A AR P100102269A AR 077241 A1 AR077241 A1 AR 077241A1
- Authority
- AR
- Argentina
- Prior art keywords
- cancer
- treatment
- antigen binding
- binding fragment
- human antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente proporciona métodos para tratar diversos tipos de cáncer/tumor, administrando la combinacion de antagonistas de DII4, en particular anticuerpos DII4 y fragmentos de los mismos que se unen específicamente a DII4 humano y agentes quimioterapéuticos. Terapias de combinacion de este tipo exhiben efectos sinérgicos en comparacion con el tratamiento con cualquier agente solo. Así, los métodos de la presente son particularmente beneficiosos para pacientes de cáncer, quienes tienen una baja tolerancia a los efectos secundarios provocados por altas dosificaciones requeridas para el tratamiento por cualquier agente solo, al ser capaces de reducir dosificaciones efectivas. También se proporcionan composiciones farmacéuticas y kits que contienen antagonistas de DII4 y agentes quimioterapéuticos. Reivindicacion 1: Un anticuerpo humano o fragmento de union a antígenos del mismo que se une específicamente a ligando similar a delta 4 humano (hDll4) para uso en el tratamiento del cáncer o para reducir o detener el crecimiento del tumor en un sujeto mediante administracion en combinacion con un agente quimioterapéutico, en donde el anticuerpo humano o fragmento de union a antígenos del mismo comprende una region variable de cadena pesada (HCVR) que comprende secuencias CDR1, CDR2 y CDR3 de cadena pesada de SEQ ID Ns:22, 24 y 26, respectivamente, y una region variable de cadena ligera (LCVR) que comprende secuencias CDR1 CDR2 y CDR3 de cadena ligera de SEQ ID Ns:30, 32 y 34, respectivamente. Reivindicacion 5: El anticuerpo humano o fragmento de union a antígenos de una cualquiera de las reivindicaciones precedentes, en donde el agente quimioterapéutico es al menos uno seleccionado del grupo que consiste en un agente anti-mitotico, agente quimioterapéutico basado en platino, inhibidor del receptor tirosina quinasa, análogo de pirimidina, inhibidor de topoisomerasa, y adyuvante. Reivindicacion 13: El anticuerpo humano o fragmento de union a antígenos de una cualquiera de las reivindicaciones precedentes, en donde el cáncer tratado se selecciona del grupo que consiste en cáncer de ovarios, cáncer de utero, cáncer de mama, cáncer de pulmon, cáncer de hígado, cáncer colorrectal, cáncer de vejiga, cáncer renal, cáncer de prostata, cáncer pancreático, cáncer de estomago, cáncer de huesos, cáncer de piel, leucemia y sarcoma de tejido blando maligno.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22046509P | 2009-06-25 | 2009-06-25 | |
US30188110P | 2010-02-05 | 2010-02-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR077241A1 true AR077241A1 (es) | 2011-08-10 |
Family
ID=42668243
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP100102269A AR077241A1 (es) | 2009-06-25 | 2010-06-25 | Metodo de tratamiento del cancer conantagonista dll4 y agente quimioterapeutico |
Country Status (28)
Country | Link |
---|---|
US (3) | US8518887B2 (es) |
EP (1) | EP2445528B1 (es) |
JP (2) | JP6038650B2 (es) |
KR (1) | KR101750723B1 (es) |
CN (1) | CN102481365A (es) |
AR (1) | AR077241A1 (es) |
AU (1) | AU2010266004B2 (es) |
BR (1) | BRPI1011818A2 (es) |
CA (1) | CA2766163C (es) |
DK (1) | DK2445528T3 (es) |
ES (1) | ES2556804T3 (es) |
HK (1) | HK1169328A1 (es) |
HR (1) | HRP20160045T1 (es) |
HU (1) | HUE026356T2 (es) |
IL (1) | IL216952A (es) |
ME (1) | ME02296B (es) |
MX (1) | MX2011013424A (es) |
MY (1) | MY173234A (es) |
PL (1) | PL2445528T3 (es) |
PT (1) | PT2445528E (es) |
RS (1) | RS54477B1 (es) |
RU (1) | RU2571220C2 (es) |
SG (2) | SG176791A1 (es) |
SI (1) | SI2445528T1 (es) |
SM (1) | SMT201500315B (es) |
TW (1) | TWI513465B (es) |
UY (1) | UY32739A (es) |
WO (1) | WO2010151770A1 (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2448979C2 (ru) * | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
TWI513465B (zh) | 2009-06-25 | 2015-12-21 | Regeneron Pharma | 以dll4拮抗劑與化學治療劑治療癌症之方法 |
DK2488204T3 (en) | 2009-10-16 | 2016-06-06 | Oncomed Pharm Inc | Therapeutic combination and use of DLL4 antagonist antibodies and blood pressure lowering agents |
WO2012092539A2 (en) * | 2010-12-31 | 2012-07-05 | Takeda Pharmaceutical Company Limited | Antibodies to dll4 and uses thereof |
HRP20230078T1 (hr) | 2011-09-23 | 2023-05-12 | Mereo Biopharma 5, Inc. | Sredstva za vezivanje vegf/dll4 i njihova uporaba |
GB2523211B (en) | 2012-01-27 | 2020-03-18 | Univ Jefferson | MCT protein inhibitor-related prognostic and therapeutic methods |
US20150240240A1 (en) * | 2012-09-13 | 2015-08-27 | Thomas Jefferson University | Msf reprograms myofibroblasts toward lactate production and fuel anaerboic tumor growth |
US9599620B2 (en) * | 2012-10-31 | 2017-03-21 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a DLL4 antagonist |
AR093445A1 (es) * | 2012-11-14 | 2015-06-10 | Regeneron Pharma | Metodos para tratar el cancer de ovario con antagonistas de dll4 |
WO2014172627A1 (en) | 2013-04-19 | 2014-10-23 | Thomas Jefferson University | Caveolin-1 related methods for treating glioblastoma with temozolomide |
US20170143787A1 (en) * | 2014-02-19 | 2017-05-25 | Pertinax Therapeutics Inc. | Chemokine receptor antagonist and its combinational therapy |
ES2808153T3 (es) | 2014-10-31 | 2021-02-25 | Mereo Biopharma 5 Inc | Terapia de combinación para tratamiento de enfermedad |
JP2018528970A (ja) * | 2015-09-16 | 2018-10-04 | サントル、ナショナール、ド、ラ、ルシェルシュ、シアンティフィク、(セーエヌエルエス) | 悪性腫瘍を治療および/または腫瘍再発を予防するためのゲル化組成物 |
WO2017053705A1 (en) | 2015-09-23 | 2017-03-30 | Oncomed Pharmaceuticals, Inc. | Methods and compositions for treatment of cancer |
CN110339350A (zh) | 2019-07-25 | 2019-10-18 | 广州中科蓝华生物科技有限公司 | 一种抗肿瘤的联合用药物组合物及其应用 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
GEP20063752B (en) | 2000-10-13 | 2006-02-27 | Biogen Inc | Humanized Anti-LT-Beta-R Antibodies |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US7138370B2 (en) | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
EP1656391B1 (en) | 2003-08-13 | 2010-10-13 | Pfizer Products Inc. | Modified human igf-1r antibodies |
US20060134121A1 (en) | 2004-10-29 | 2006-06-22 | Gavin Thurston | DII4 antagonists, assays, and therapeutic methods thereof |
US20070213266A1 (en) | 2005-09-01 | 2007-09-13 | Vasgene Therapeutics, Inc. | Methods for using and identifying modulators of Delta-like 4 |
US8329408B2 (en) * | 2005-10-31 | 2012-12-11 | Bayer Healthcare Llc | Methods for prognosis and monitoring cancer therapy |
NZ568739A (en) * | 2005-12-16 | 2010-09-30 | Regeneron Pharma | Therapeutic methods for inhibiting tumor growth with delta-like ligand 4 antagonists |
US7695913B2 (en) * | 2006-01-11 | 2010-04-13 | Genomic Health, Inc. | Gene expression markers for colorectal cancer prognosis |
KR20090027227A (ko) | 2006-06-06 | 2009-03-16 | 제넨테크, 인크. | 항-dll4 항체 및 이의 사용 방법 |
CL2007001624A1 (es) | 2006-06-06 | 2008-01-18 | Genentech Inc | Uso de un anticuerpo que se une a dll4 para el tratamiento de tumor, cancer o trastorno de proliferacion celular. |
PT2066694E (pt) | 2006-09-29 | 2016-01-27 | Oncomed Pharm Inc | Composições e métodos de diagnóstico e tratamento do cancro |
RU2448979C2 (ru) * | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
US20100119526A1 (en) * | 2007-01-26 | 2010-05-13 | Bioinvent International Ab | DLL4 Signaling Inhibitors and Uses Thereof |
EP1958632A1 (en) * | 2007-02-14 | 2008-08-20 | Dan Stoicescu | Use of condensed pyrimidine derivatives for the treatment of autoimmune and inflammatory diseases |
AU2009294415B2 (en) * | 2008-09-19 | 2015-09-24 | Medimmune Llc | Antibodies directed to DLL4 and uses thereof |
EP2356146A1 (en) * | 2008-11-07 | 2011-08-17 | Fabrus Llc | Anti-dll4 antibodies and uses thereof |
TWI513465B (zh) | 2009-06-25 | 2015-12-21 | Regeneron Pharma | 以dll4拮抗劑與化學治療劑治療癌症之方法 |
-
2010
- 2010-06-24 TW TW099120547A patent/TWI513465B/zh not_active IP Right Cessation
- 2010-06-25 ME MEP-2015-185A patent/ME02296B/me unknown
- 2010-06-25 SI SI201031078T patent/SI2445528T1/sl unknown
- 2010-06-25 BR BRPI1011818A patent/BRPI1011818A2/pt not_active IP Right Cessation
- 2010-06-25 PT PT107285553T patent/PT2445528E/pt unknown
- 2010-06-25 DK DK10728555.3T patent/DK2445528T3/en active
- 2010-06-25 WO PCT/US2010/039999 patent/WO2010151770A1/en active Application Filing
- 2010-06-25 MX MX2011013424A patent/MX2011013424A/es active IP Right Grant
- 2010-06-25 RS RS20150865A patent/RS54477B1/en unknown
- 2010-06-25 UY UY0001032739A patent/UY32739A/es unknown
- 2010-06-25 US US12/823,680 patent/US8518887B2/en active Active
- 2010-06-25 MY MYPI2011005985A patent/MY173234A/en unknown
- 2010-06-25 JP JP2012517770A patent/JP6038650B2/ja active Active
- 2010-06-25 HU HUE10728555A patent/HUE026356T2/en unknown
- 2010-06-25 AR ARP100102269A patent/AR077241A1/es unknown
- 2010-06-25 ES ES10728555.3T patent/ES2556804T3/es active Active
- 2010-06-25 SG SG2011091642A patent/SG176791A1/en unknown
- 2010-06-25 PL PL10728555T patent/PL2445528T3/pl unknown
- 2010-06-25 SG SG10201403568RA patent/SG10201403568RA/en unknown
- 2010-06-25 RU RU2012102415/10A patent/RU2571220C2/ru not_active IP Right Cessation
- 2010-06-25 EP EP10728555.3A patent/EP2445528B1/en active Active
- 2010-06-25 AU AU2010266004A patent/AU2010266004B2/en active Active
- 2010-06-25 CA CA2766163A patent/CA2766163C/en active Active
- 2010-06-25 CN CN201080037619XA patent/CN102481365A/zh active Pending
- 2010-06-25 KR KR1020127001947A patent/KR101750723B1/ko active IP Right Grant
-
2011
- 2011-12-13 IL IL216952A patent/IL216952A/en not_active IP Right Cessation
-
2012
- 2012-10-15 HK HK12110142.2A patent/HK1169328A1/xx not_active IP Right Cessation
-
2013
- 2013-07-23 US US13/948,919 patent/US8840886B2/en active Active
-
2014
- 2014-08-12 US US14/457,968 patent/US20150064189A1/en not_active Abandoned
-
2015
- 2015-08-14 JP JP2015160020A patent/JP2016006101A/ja not_active Withdrawn
- 2015-12-15 SM SM201500315T patent/SMT201500315B/it unknown
-
2016
- 2016-01-14 HR HRP20160045TT patent/HRP20160045T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR077241A1 (es) | Metodo de tratamiento del cancer conantagonista dll4 y agente quimioterapeutico | |
AU2013327116B2 (en) | Combination of anti-KIR antibodies and anti-PD-1 antibodies to treat cancer | |
Gao et al. | Anti-VEGF/VEGFR2 monoclonal antibodies and their combinations with PD-1/PD-L1 inhibitors in clinic | |
RU2404806C2 (ru) | Продление времени до прогрессирования заболевания или продолжительности жизни у онкологических больных с применением ингибиторов димеризации her | |
JP6416197B2 (ja) | 癌の治療のための医薬の調製のためのクローディン18.2に対する抗体の使用 | |
RU2011111746A (ru) | Композиции рекомбинантных антител против рецептора эпидермального фактора роста | |
RU2007101378A (ru) | Терапия злокачественной опухоли, резистентной к препаратам на основе платины | |
RU2012137505A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
JP2019519499A5 (es) | ||
RU2014108045A (ru) | Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли | |
RU2014108043A (ru) | Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли | |
MX2021011500A (es) | Anticuerpos multiespecificos egfr x cd28. | |
JP2008503476A5 (es) | ||
JP2018536624A5 (es) | ||
EP2190480A4 (en) | ANTI-IGR-1R ANTIBODIES AND ITS USES | |
AR104812A1 (es) | Combinaciones terapéuticas y métodos para tratar neoplasias | |
RU2009132674A (ru) | Комбинированная терапия с использованием ингибиторов ангиогенеза | |
RU2017108173A (ru) | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 | |
RU2016147206A (ru) | Полипептиды и полинуклеотиды и их применение для лечения иммунологических нарушений и рака | |
MX2008015498A (es) | Tratamiento de cancer de mama metastasico. | |
MX2009011226A (es) | Inhibidores especificos pdgfrbeta. | |
IL278574B1 (en) | Compounds acting on glycans and methods of using them | |
JP2020511481A5 (es) | ||
AR093445A1 (es) | Metodos para tratar el cancer de ovario con antagonistas de dll4 | |
US20210023211A1 (en) | Combination of anti-fgfr4-antibody and bile acid sequestrant |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |